In fact, CCL5 promotes Treg infiltration, and cancer-FoxP3 (C-FoxP3) expressed on these T-regs promotes PD-L1 expression, which rationalizes targeting CCL5 in combination with PD-L1 inhibitors. Here, FOXP3 is linked to cancer.